GARY S JACOB
CIK 1266802 · Chief Executive Officer · last filed 2024-02-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$53.7K
Companies
10
Total Filings
54
Lifetime Open-Market Net
$163.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HEPA | Director | 12,059 | $0.08 | $965 | $19.9K | 6 | 2024-02-21 |
| OKYO | Chief Executive Officer | 12,500 | $1.52 | $19.0K | $50.0K | 1 | 2022-05-19 |
| VRPX | Director | 3,500 | $0.00 | $1 | $23.8K | 3 | 2022-01-05 |
| CRDF | Director | 21,922 | $1.54 | $33.8K | $49.7K | 4 | 2021-06-15 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | 148,954 | — | — | $0 | 5 | 2019-06-24 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 2 | 2018-07-03 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Executive Chairman | 595,460 | — | — | $20.0K | 4 | 2018-06-18 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Director | — | — | — | $0 | 7 | 2017-01-05 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Chief Executive Officer | 396,999 | — | — | $0 | 13 | 2016-06-27 |
| CALLISTO PHARMACEUTICALS INC (KAL) Delisted | Chief Executive Officer | 147,425 | $1.12 | $165.1K | $0 | 2 | 2007-10-25 |
Recent Filings · Page 2 of 6
54 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-19 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2020-05-18 | CRDF | Buy (P) | +17,483 | $25.0K | EDGAR |
| 2020-04-07 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2019-07-25 | HEPA | Grant (A) | — | $0 | EDGAR |
| 2019-06-24 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Buy (P) | — | $0 | EDGAR |
| 2018-06-18 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Mixed | +192,781 | $237.5K | EDGAR |
| 2018-01-25 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-09 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Exer (M) | +16,667 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.